Trial Profile

A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HBM-1020 (Primary)
Indications Adenocarcinoma; Colorectal cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions
Sponsors Harbour BioMed

Most Recent Events

14 Sep 2024 According to a Harbour BioMed media release, data from this study were presented at the ESMO Congress 2024.
14 Sep 2024 Results presented in a Harbour BioMed Media Release.
25 Jul 2024 According to a Harbour BioMed media release, latest clinical data from this trial will be presented at the ESMO Congress 2024, taking place from September 13-17, 2024, in Barcelona, Spain.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com